Stockwatch: Stale M&A And Valuations Limit A Sector Recovery
This article was originally published in Scrip
Executive Summary
Last week the S&P 500 and NASDAQ Biotechnology (NBI) Indexes both finished the shortened trading week up about 1.3%. On the one hand, there's nothing like a long weekend to shift investors' perspective over to the sunny side of the street. On the other, the share prices of life science stocks remain volatile and investment bank analysts are still playing catch-up with downgrades to company share price targets.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.